GlassScriptPhysician profile
Kimberly Hagedorn
NPI 1669832556
$3,773.82
in general payments reported to CMS, 2019-2025
32 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 89% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $612 · 2023: $845 · 2024: $529 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.14 |
| Education | $207.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $895.84 | 2021-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $405.75 | 2021-2025 | |
| Incyte Corporation | $394.21 | 2022-2025 | Jakafi, Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $350.35 | 2021-2025 | Imfinzi, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $298.28 | 2021-2025 | Carvykti, Rybrevant, Darzalex |
| Abbvie INC. | $174.79 | 2021-2025 | |
| Genzyme Corporation | $169.71 | 2023-2025 | |
| Tempus Ai, INC | $137.01 | 2025 | Xt Cdx |
| Genentech USA, INC. | $116.63 | 2023-2025 | Lunsumio, Polivy, Tecentriq Hybreza |
| Amgen INC. | $100.39 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Merck Sharp & Dohme LLC | $82.94 | 2023-2025 | Verquvo, Keytruda, Belsomra |
| Regeneron Healthcare Solutions, INC. | $75.43 | 2021-2023 | Libtayo |
| Aveo Pharmaceuticals, INC. | $66.87 | 2022-2023 | Fotivda |
| Celgene Corporation | $65.60 | 2023 | Reblozyl |
| Seagen INC. | $45.67 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.73 | 2023-2025 | Shingrix, Ojjaara |
| Emd Serono, INC. | $35.92 | 2025 | |
| Karyopharm Therapeutics INC. | $31.66 | 2024-2025 | Xpovio |
| Lilly USA, LLC | $31.19 | 2025 | Verzenio, Jaypirca |
| Stemline Therapeutics INC. | $31.05 | 2023 | Orserdu |
| Eisai INC. | $29.62 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $23.89 | 2023 | Rezlidhia, Tavalisse |
| Pharmacosmos Therapeutics INC. | $19.88 | 2025 | Monoferric |
| Beigene USA, INC. | $19.75 | 2023 | Brukinsa |
| Array Biopharma INC | $19.38 | 2025 | Xalkori, Braftovi, Mektovi |
| Daiichi Sankyo INC. | $18.81 | 2025 | Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2025 | Fruzaqla |
| Pfizer INC. | $17.52 | 2025 | |
| Taiho Oncology, INC. | $15.58 | 2024 | |
| Aadi Bioscience, INC. | $15.52 | 2022 | |
| Progenics Pharmaceuticals, INC. | $15.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Hagedorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.